| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer IF Tannock, R De Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, ... New England Journal of Medicine 351 (15), 1502-1512, 2004 | 7213 | 2004 |
| Mortality results from a randomized prostate-cancer screening trial GL Andriole, ED Crawford, RL Grubb III, SS Buys, D Chia, TR Church, ... New England journal of medicine 360 (13), 1310-1319, 2009 | 3937 | 2009 |
| Natural history of progression after PSA elevation following radical prostatectomy CR Pound, AW Partin, MA Eisenberger, DW Chan, JD Pearson, PC Walsh Jama 281 (17), 1591-1597, 1999 | 3730 | 1999 |
| Chemohormonal therapy in metastatic hormone-sensitive prostate cancer CJ Sweeney, YH Chen, M Carducci, G Liu, DF Jarrard, M Eisenberger, ... New England Journal of Medicine 373 (8), 737-746, 2015 | 2838 | 2015 |
| AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... New England Journal of Medicine 371 (11), 1028-1038, 2014 | 2804 | 2014 |
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical … HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ... Journal of clinical oncology: official journal of the American Society of …, 2008 | 2407 | 2008 |
| A controlled trial of leuprolide with and without flutamide in prostatic carcinoma ED Crawford, MA Eisenberger, DG McLeod, JT Spaulding, R Benson, ... New England Journal of Medicine 321 (7), 419-424, 1989 | 1898 | 1989 |
| Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy SJ Freedland, EB Humphreys, LA Mangold, M Eisenberger, FJ Dorey, ... Jama 294 (4), 433-439, 2005 | 1630 | 2005 |
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study DR Berthold, GR Pond, F Soban, R De Wit, M Eisenberger, IF Tannock Journal of Clinical Oncology 26 (2), 242-245, 2008 | 1453 | 2008 |
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study DR Berthold, GR Pond, F Soban, R De Wit, M Eisenberger, IF Tannock Journal of Clinical Oncology 26 (2), 242-245, 2008 | 1453 | 2008 |
| Bilateral orchiectomy with or without flutamide for metastatic prostate cancer MA Eisenberger, BA Blumenstein, ED Crawford, G Miller, DG McLeod, ... New England Journal of Medicine 339 (15), 1036-1042, 1998 | 1143 | 1998 |
| Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ... Journal of Clinical Oncology 17 (11), 3461-3467, 1999 | 1140 | 1999 |
| Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial CE Kyriakopoulos, YH Chen, MA Carducci, G Liu, DF Jarrard, NM Hahn, ... Journal of Clinical Oncology 36 (11), 1080, 2018 | 932 | 2018 |
| Cancer-related fatigue, version 2.2015 AM Berger, K Mooney, A Alvarez-Perez, WS Breitbart, KM Carpenter, ... Journal of the National Comprehensive Cancer Network 13 (8), 1012-1039, 2015 | 830 | 2015 |
| Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis, SP Rowe, ... JAMA oncology 6 (5), 650-659, 2020 | 800 | 2020 |
| Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate JB Nelson, SP Hedican, DJ George, AH Reddi, S Piantadosi, ... Nature medicine 1 (9), 944-949, 1995 | 779 | 1995 |
| Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer W Liu, S Laitinen, S Khan, M Vihinen, J Kowalski, G Yu, L Chen, ... Nature medicine 15 (5), 559-565, 2009 | 741 | 2009 |
| Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ... JAMA oncology 1 (5), 582-591, 2015 | 675 | 2015 |
| NCCN Practice Guidelines for Cancer-Related Fatigue. V Mock, A Atkinson, A Barsevick, D Cella, B Cimprich, C Cleeland, ... Oncology (Williston Park, NY) 14 (11A), 151-161, 2000 | 655 | 2000 |
| Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer Z Szabo, E Mena, SP Rowe, D Plyku, R Nidal, MA Eisenberger, ... Molecular imaging and biology 17, 565-574, 2015 | 487 | 2015 |
